Graft Versus Host Disease
Keywords:
-Abstract
-
Downloads
References
Sullivan KM. Graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic cell transplantation. 2nd ed. Malden: Blackwell Science, Inc 1999:515-36
Jootar S, Intragumtornchai T, Chuncharunee S, Seksan P, Hathirat P. Low incidence of acute graft versus host disease in Thai patients after allogeneic bone marrow transplantation. Transplant Proc 1994:26:2354-6.
Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001:19:3685-91.
Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966;62:21-78.
Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S, et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA identical siblings. Blood 2002:100:724-7.
Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999;94:1465-70.
Socie G, Loiseau P, Tamouza R, Janin A, Busson M, Gluckman E, et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001;72:699-706.
Tseng LH, Lin MT, Hansen JA, Gooley T, Pei J, Smith AG, et aLl. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1999,94:2911-4.
Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 200248:674-82.
Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglund H, Klaesson S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998;22:755-61.
Ferrara JLM, Antin JH. The pathophysiology of graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic cell transplantation. 2nd ed. Malden: Blackwell Science, Inc 1999:305-15.
Shizuru JA. Chronic graft-versus-host disease: a double-edged sword. In: Broudy VC, Abkowitz JL, Vose JM, eds. Hematology 2002. Seattle: Am Soc Hematol 2002:408-21.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
Weisdorf DJ, Snover DC, Haake R, Miller WJ, McGlave PB, Blazar B, et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990;76:624-9.
Wakui M, Okamoto S, Ishida A, Kobayashi H, Watanabe R, Yajima T, et al. Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 1999,23:573-8.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
Akpek G. Clinical grading in chronic graft-versus-host disease: is it time for change? Leuk Lymphoma 2002:43:1211-20.
Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5.
Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial.
Blood 1989;73:1729-34
Sullivan KM. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Clin Exp Immunol 1996;104(Suppl 1):43-8.
Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98:3192-204
Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991;78:2120-30.
Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001;98:934-9.
Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K, et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marow transplantation. A randomized controlled trial. Transplantation 1994;57:82-7.
Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999:340:1704-14.
Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990;76:1464-72.
Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 2001;15:147-53.
Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981;57:267-76.
Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: progmostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988;72:546-54.
Gaziev D, Galimberti M, Lucarelli G, Polchi P. Chronic graft-versus-host disease: is there an alternative to the conventional treatment? Bone Marrow Transplant 2000:25:689-96.
Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995;86:3604-9.
Kanamaru A, Takemoto Y, Kakishita E, Doby H, Kodera Y, Moriyama Y, et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant 1995;15:885-9.
Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 2001,27:1255-62.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
